tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2020 Dec 1.
doi: 10.1111/jdv.17051. Online ahead of print.
Lack of skin manifestations in COVID-19 hospitalized patients during the second epidemic wave in Spain: a possible association with a novel SARS-CoV-2 variant. A cross-sectional study
D Fernandez-Nieto[SUP] 1 [/SUP], D Ortega-Quijano[SUP] 1 [/SUP], A Suarez-Valle[SUP] 1 [/SUP], J Jimenez-Cauhe[SUP] 1 [/SUP], P Jaen-Olasolo[SUP] 1 [/SUP], M Fernandez-Guarino[SUP] 1 [/SUP]
Affiliations
Abstract
The Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Skin lesions have been described in confirmed COVID-19 patients as potential manifestations of the disease[SUP]1[/SUP] . Different prevalence rates have been reported in hospitalized patients from January to May 2020, ranging from 0.2 to 20.5%.[SUP]2-5[/SUP] Prevalence rates in studies where dermatologists did not perform the initial physical examination may be underestimated[SUP]2,5,6[/SUP] . A second wave of the COVID-19 epidemic has emerged in European countries starting in late August. Spain has been one of the most affected regions. However, cutaneous findings have been scarcely reported during this time period.
Keywords: SARS; chilblain; coronavirus; exanthem; virus.
. 2020 Dec 1.
doi: 10.1111/jdv.17051. Online ahead of print.
Lack of skin manifestations in COVID-19 hospitalized patients during the second epidemic wave in Spain: a possible association with a novel SARS-CoV-2 variant. A cross-sectional study
D Fernandez-Nieto[SUP] 1 [/SUP], D Ortega-Quijano[SUP] 1 [/SUP], A Suarez-Valle[SUP] 1 [/SUP], J Jimenez-Cauhe[SUP] 1 [/SUP], P Jaen-Olasolo[SUP] 1 [/SUP], M Fernandez-Guarino[SUP] 1 [/SUP]
Affiliations
- PMID: 33259091
- DOI: 10.1111/jdv.17051
Abstract
The Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Skin lesions have been described in confirmed COVID-19 patients as potential manifestations of the disease[SUP]1[/SUP] . Different prevalence rates have been reported in hospitalized patients from January to May 2020, ranging from 0.2 to 20.5%.[SUP]2-5[/SUP] Prevalence rates in studies where dermatologists did not perform the initial physical examination may be underestimated[SUP]2,5,6[/SUP] . A second wave of the COVID-19 epidemic has emerged in European countries starting in late August. Spain has been one of the most affected regions. However, cutaneous findings have been scarcely reported during this time period.
Keywords: SARS; chilblain; coronavirus; exanthem; virus.